Aziyo Biologics appoints David Colpman to board; regains Nasdaq audit committee compliance

ELUTIA INC.

David Colpman appointed to Board of Directors and audit committee effective Oct. 20, 2022; board size increased to six.
Colpman brings over 25 years of healthcare business development experience, including senior roles at Shire, Novo Nordisk, Glaxo Wellcome.
Appointment resolves Nasdaq noncompliance with Rule 5605(c)(2) (audit committee independence deficiency) created by Dr. Mills' role change.
Colpman currently serves as advisor to HighCape Capital, affiliate of HighCape Partners, a controlling stockholder of Aziyo.
CEO Dr. Randy Mills highlights Colpman's transaction experience as valuable for strategic partnerships and near-term priorities.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Colpman

Director

ELUT · ELUTIA INC.

Effective: 2022-10-20
Filed: October 24, 2022, 7:59 PM ET

the Company) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Colpman was appointed as Director at ELUTIA INC..

Action: appointed
Role: Director

Exact text from the filing

the Company) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately.

View on SEC.gov

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-110797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.